AGENDIA Inc.

Agendia Inc. is a molecular diagnostics company specializing in genomic testing for early-stage breast cancer. The company develops and provides MammaPrint and BluePrint, two FDA-cleared genomic profiling tests that analyze tumor biology to assess recurrence risk and determine molecular subtype. MammaPrint is a 70-gene recurrence risk assay for HR+/HER2− early-stage breast cancer patients, while BluePrint is a molecular subtyping test that identifies the underlying genomic drivers of tumor growth. Results are delivered within 6 business days from a single tissue sample. These tests enable oncologists to personalize treatment decisions and reduce both under- and over-treatment. Agendia's assays are validated by multiple landmark clinical studies and recognized by major treatment guidelines including NCCN (National Comprehensive Cancer Network). The company serves leading physicians and institutions globally and maintains CLIA, CAP, and ISO certifications for laboratory operations. Agendia operates a CLIA-certified laboratory and provides test ordering through multiple physician portals. The company markets its services to oncology practices, cancer centers, and health systems in the Americas, Europe, and internationally.